Also known as: Acurx, Acurx Pharmaceuticals
Acurx Pharmaceuticals is a clinical-stage biopharmaceutical company developing antibiotic candidates for difficult bacterial infections. Its lead program is ibezapolstat for C. difficile infections, with additional candidates targeting drug-resistant Gram-positive bacteria.
Acurx Pharmaceuticals announced a new clinical trial program for ibezapolstat in patients with recurrent C. difficile infection, building on Phase 2 results showing 96% clinical cure rates with no recurrence while sparing the gut microbiome.
Acurx Pharmaceuticals will discuss full year and fourth quarter 2025 financial results on March 13, 2026, and provide updates on ibezapolstat, its lead antibiotic candidate preparing for international Phase 3 trials for C. difficile infection.
